close this window
Complete the following form to e-mail a copy of this event to a friend.
Hello, The following event may be of interest to you: Bottleneck in the Drug Pipeline?Alternative Tumor Measurement-based Phase II Clinical Trial Endpoints for Predicting Overall Survival Tuesday, October 24, 2017 In the final stages of a long and costly drug discovery process, a drug compound is introduced into humans as part of a clinical trial. A clinical trial is a research study with a pre-defined protocol and is conducted in different phases. In oncology, as many as 60% of drug compounds that reach the last phase (Phase III) fail this final step. This high failure rate may reflect inappropriate evaluation of compounds in preceding Phase II trials, in which the primary endpoint is often binary tumor response, based on the Response Evaluation Criteria for Solid Tumors (RECIST). This motivates the search for alternative Phase II endpoints. In this talk, we will introduce clinical trials and survival analysis to contextualize the problem. Then we will describe our work evaluating alternative categorical and continuous tumor measurement-based endpoints for their ability to predict overall survival using data from real clinical trials. Time: 12:00 pm EDT/GMT-4 Location: Hegeman 204 Sponsor: Mathematics Program Contact: Lauren Rose. E-mail: [email protected] Phone: 845-758-7362 If you would like to see more events please visit the following URL: http://www.bard.edu/academics/programs/physics/events/